REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Preparations Characterized By Special Physical Form > Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets) Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets)Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178164 - Pharmaceutical formulations of oxcarbazepine and methods for its preparation The present invention provides a pharmaceutical composition comprising oxcarbazepine and at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution and an enhanced oxcarbazepine dissolution rate. The broad particle size distribution of oxcarbazepine in the pharmaceutical composition is preferably a multi-modal oxcarbazepine particle ... 08/02/07 - 20070178163 - Gas dispersion manufacture of nanoparticulates, and nanoparticulate-containing products and processing thereof In one aspect, the present invention relates to a method of making multi-phase particles that include nanoparticulates and matrix, which maintains the nanoparticulates in a dispersed state. A flowing gas dispersion is generated that includes droplets of a precursor medium dispersed in a gas phase. The precursor medium contains liquid ... 08/02/07 - 20070178162 - Process for production of ionically crosslinked polysaccharide microspheres The invention relates to a process for preparing microspheres comprising an ionically crosslinked polymer, the process comprising: (a) producing liquid aerosol droplets (13) from a solution (3) comprising an ionically crosslinkable polyionic polymer into a continuous gas stream by using an ultrasonic nebulizer; (b) transferring the gas stream into a ... 08/02/07 - 20070178161 - Use of n-acetryl-d-glucosamine in treating and controlling non-specific inflammations caused by physical or chemical factors The present invention relates to a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating non-specific inflammations caused by physical/chemical factors and controlling symptoms thereof. A preparation comprising N-acetyl-D-glucosamine as main active component for treating non-specific inflammations caused by physical/chemical factors exhibits merits of significant therapeutical effects and ... 07/19/07 - 20070166388 - Combinations and modes of administration of therapeutic agents and combination therapy The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as ... 07/19/07 - 20070166387 - Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from chitosan and including a polymer mesh material of poly-4-hydroxy butyrate A granule or particle made of a chitosan material either carries within it a polymer mesh material of poly-4-hydroxy butyrate, or has interspersed with it a polymer mesh material of poly-4-hydroxy butyrate. The granule or particle can be carried within a polymer mesh socklet made of a material consisting essentially ... 07/19/07 - 20070166386 - Nanoparticle formation of pharmaceutical ingredients A pharmaceutical ingredient is dissolved within a solvent. The solvent is evaporated until nanoparticles of the pharmaceutical ingredient are at least partially formed without employing a substrate for them. A portion of the solvent remains, within which the nanoparticles are located. ... 07/19/07 - 20070166385 - Method of inhibiting restenosis using bisphosphonates A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly ... 07/12/07 - 20070160676 - Stable dispersion of dbnpa in viscosified brine A dispersion of 2,2-dibromo-3-nitrilopropionamide (“DBNPA”) particles in a restrictedly viscosified concentrated brine solution effectively negates gelling of the brine solution because the naturally occurring gum used does not exhibits Ellis-Plastic behavior in the concentrated brine at a pH of from about 1 to 4. Because the DBNPA particles are much ... 07/12/07 - 20070160675 - Nanoparticulate and controlled release compositions comprising a cephalosporin The present invention provides a composition comprising cephalosporin useful in the treatment and prevention of a bacterial infection. In one embodiment, the composition comprises nanoparticulate particles comprising cephalosporin and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In ... 07/12/07 - 20070160674 - Method for producing calcium component powder containing oil-soluble substance The present invention provides a method for producing a powder containing an oil-soluble substance, fromn which substantially no oil-soluble substances are eluted upon application of pressure, heat, or water. The present invention relates to a method for producing a powder containing an oil-soluble substance, which comprises, dispersing an oil-soluble substance ... 07/12/07 - 20070160673 - Amoxicilline instant granulate A novel process for preparing stable granulate which comprises amoxicillin trihydrate and a sugar, and to novel stable granulate comprising amoxicillin trihydrate and the sugar as well, for reconstitution with water into fine stable homogeneous aqueous suspension is described. The novel process omits preliminary process step for preparing fine particle ... 07/05/07 - 20070154562 - Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2: 1, wherein the anti-tubercular drugs are in the ratio ... 07/05/07 - 20070154561 - Metal oxide particle and its uses An object of the present invention is to provide a metal oxide particle which exercises more excellent ultraviolet absorbency as a matter of course and combines therewith merits of, for example, either being shifted in ultraviolet absorption edge toward the longer wavelength side and being excellent also in the absorption ... 07/05/07 - 20070154560 - Process for producing microsphere and apparatus for producing the same A process and apparatus for producing microspheres containing an active component as to be releasable, the process comprising: preparing polymer solution or dispersion having at least active agent, solvent or dispersant, and polymer; drop-wise spitting the polymer solution or dispersion into a flowing fluid, at a predetermined temperature, as to ... 07/05/07 - 20070154559 - Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof The present invention relates to an orally administrable composition containing nanoparticles with the particle size of 500 nm or less, comprising 0.1˜30 weight % of a complex of a water-soluble drug and a counter-ion substance in which the charged water-soluble drug is bonded with the counter-ion substance, 0.5˜80 weight % ... 06/28/07 - 20070148253 - Modified release formulation of lithium carbonate and method for preparation thereof Modified release formulation of lithium carbonate in microgranules or similar comprising, for around 300 Kg of Lithium Carbonate, at least: Overall Povidone in quantity between 8.0 Kg and 40.0 Kg; Ethylcellulose in quantity between Kg 0.9 and Kg 3.6. ... 06/28/07 - 20070148252 - Solid ganaxolone formulations and methods for the making and use thereof In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. ... 06/28/07 - 20070148251 - Nanoparticle releasing medical devices Nanoparticles comprising a matrix or shell material and a bioactive agent and medical devices containing the nanoparticles are provided. ... 06/28/07 - 20070148250 - Loading of a camptothecin drug into colloidal nanoparticles The present invention relates to an improved method of producing a colloidal nanoparticulate preparation comprising a camptothecin drug in its carboxylate form, a kit and a pharmaceutical composition. ... 06/28/07 - 20070148249 - Method of preparation of oral solid dosage form with instant release of acting A method of preparation of an oral solid dosage form with instant release of an active agent containing as the active agent finasteride characterized in that an aqueous suspension containing 5% to 50% by weight of finasteride, based on the total weight of the suspension, and 0.1 to 50% by ... 06/21/07 - 20070141162 - Injectable compositions for the controlled delivery of pharmacologically active compound The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic ... 06/21/07 - 20070141161 - Liquid ganaxolone formulations and methods for the making and use thereof In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. ... 06/21/07 - 20070141160 - Method of treatment for osteoarthritis by local intra-articular injection of microparticles A method of treatment of osteoarthritis is described, where a therapeutically effective amount of a composition having biodegradable microparticles in an aqueous vehicle is delivered into the intra-articular space of a joint. In one aspect, the microparticle-containing composition is injected into the synovial fluid-containing portion of an affected joint. ... 06/21/07 - 20070141159 - Methods of making nanoparticulate drug compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, ... 06/21/07 - 20070141158 - Amphiphilic heparin derivative formed by coupling a heparin with a bile acid The invention relates to an amphiphilic heparin derivative formed from at least one type of partially N-desulfated heparin and at least one type of bile acid comprising one or several bile acid molecules grafted on a heparin molecule by an amide bond formed between the terminal carboxylic acid function of ... 06/14/07 - 20070134343 - Collagen-based materials and methods for treating synovial joints A method of treating a synovial joint by injecting particles of collagen-based material into the joint. The particles may be dehydrated before implantation, and rehydrated after implantation, or they may be implanted in a “wet” state—such as a slurry or gel. Radiocontrast materials may be included to enhance imaging of ... 06/14/07 - 20070134342 - Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins An injectable formulation is disclosed for delivery of osteogenic proteins. The formulation comprises a pharmaceutically acceptable admixture of an osteogenic protein; and formulations comprising osteogenic protein, hyaluronic acid derivatives and tricalcium phosphate are also disclosed. Methods for formulating porous injectable gels and pastes from hyaluronic acid are also disclosed. ... 06/14/07 - 20070134341 - Compositions of lipoxygenase inhibitors Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are ... 06/14/07 - 20070134340 - Method for delivering hydrophobic drugs via nanocrystal formulations This invention provides nanocrystals or polymer doped nanocrystals of hydrophobic drug molecules as stably dispersed in an aqueous system which are prepared without stabilizers like surfactants and the like. In one embodiment, the drug is a tetra-pyrrole compound. An example is the hydrophobic photosensitizing anticancer drug 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide (HPPH). Pharmaceutical compositions ... 06/14/07 - 20070134339 - Zonisamide and nsaid nanoparticulate formulations The present invention is directed to compositions comprising zonisamide, or a salt or derivative thereof, and at least one nanoparticulate NSAID. The zonisamide and NSAID combination preferably includes nanoparticulate NSAID particles of the composition with an effective average particle size of less than about 2000 nm. The zonisamide and NSAID ... 06/14/07 - 20070134338 - Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology Nanoparticulate metal complexes, such as those involving ruthenium, iron, cobalt, and nickel salens, are formed using precipitation with compressed antisolvent technology. The nanoparticle morphology may be altered by altering the planarity of molecular structure of the metal complex starting material. ... 06/14/07 - 20070134337 - Bacteria binding products There is provided products for the removal of negatively charged particles like bacteria from surfaces. The products have a positive charge that may be developed through the use of cationic treatments. The product or substrate from which it is made may be dipped in an aqueous solution of a non-antimicrobial ... 06/14/07 - 20070134336 - Method for improving the properties of amphiphile particles The present invention provides a method for forming a dispersion comprising non-lamellar amphiphile particles having improved phase behaviour, particle size distribution and/or storage stability, said method comprising forming a dispersion of lamellar and optionally non-lamellar particles comprising at least one structuring agent in a polar solvent, heating said particles to ... 06/07/07 - 20070128290 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts ... 06/07/07 - 20070128289 - Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases The present invention relates to nano- and/or micro-particulate formulations that can be locally injected into arterial walls at or near target sites to achieve a prolonged and sufficiently high local concentration of at least one pharmacologically active agent for treatment of vascular diseases, such as, for example, restenosis, vulnerable plaque, ... 05/31/07 - 20070122486 - Nanoparticulate insulin Nanoparticulate insulin compositions having effective an average particle size of less than about 5 microns are described. The compositions exhibit retention of insulin bioactivity, increased bioavailability, and increased consistency of bioavailability as compared to prior macro-sized insulin compositions. Methods of making nanoparticulate insulin compositions, dosage forms containing them, and the ... 05/31/07 - 20070122485 - Organic compounds A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane. ... 05/31/07 - 20070122484 - Parenterally administrable microparticles A process for producing microparticles containing biologically active substance, in which process an aqueous solution of the said substance is prepared, this solution is mixed with an aqueous solution of PEG such that the substance is concentrated and/or solidified, the substance is optionally washed, the substance is mixed with an ... 05/31/07 - 20070122483 - Fluocinolone acetonide drug substance polymorphic interconversion Disclosed in embodiments herein is a method of providing the same form of FA. Regardless of which form or mixture of forms are present by forming a slurry from samples of fluocinolone acetonide containing mostly Form A and little to no Form A. ... 05/31/07 - 20070122482 - Method for preparing modified release pharmaceutical compositions A method for the preparation of a pharmaceutical particulate composition for modified release of one or more therapeutically, prophylactically and/or diagnostically active substances, the method involving spraying of a composition comprising an oily material on a solid composition in order to subject the solid composition to a controlled agglomeration process, ... 05/24/07 - 20070116776 - Particulate drug-containing products and method of manufacture Provided is a compressed anti-solvent technique for manufacture of drug-containing powders for pulmonary delivery. The drug is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by the manufacture method, including powders of substantially pure drug and powders including a biocompatible ... 05/24/07 - 20070116775 - Plastic caviar bead for filling of pillow having function of anti-bacteria The present invention relates to the plastic caviar bead for filling of pillow having function of anti-bacteria that combines the raw materials of synthetic resins of 100 in weight, antimicrobial of 0.5˜2 in weight, ceramic with hydrogen silicon and hydrogen aluminum of 3˜15 in weight that are pressed and corrected ... 05/24/07 - 20070116774 - Methods and compositions for treating proliferative diseases The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations ... 05/24/07 - 20070116773 - Metal nanostructures and pharmaceutical compositions A metal nanostructure is described. Such a metal nanostructure may comprise a nanometric metal core comprising gold, silver or an assembly or alloy of gold and silver, and one or more molecules attached to one or more surfaces of the nanometric metal core, where each of the molecules has the ... 05/24/07 - 20070116772 - Nanoparticles for protein drug delivery The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery. ... 05/24/07 - 20070116771 - Nanoparticles for protein drug delivery The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery. ... 05/24/07 - 20070116770 - Tazobactam/piperacillin lyophilizate The present invention relates to a lyophilizate which contains tazobactam and piperacillin, a process for the preparation of this lyophilizate, the use of this lyophilizate for the preparation of a drug, and drugs which comprise this lyophilizate. ... 05/24/07 - 20070116769 - Continuous encapsulation process The present invention relates to a process for coating of particles comprising the steps of: feeding particles to a coating unit wherein said particles are coated; directly transferring coated particles from the coating unit to a separator unit; separating finished coated particles from unfinished coated particles; removing the finished coated ... 05/24/07 - 20070116768 - Sustained release preparations composed of biocompatible complex microparticles A particle includes a complex between a bioactive agent and a complexing agent, provided that the bioactive agent is other than a polynucleotide and an oligonucleotide, and wherein the particle has a bioactive function. The particle has a diameter from about 5 nm to about 100 microns. In certain embodiments, ... 05/24/07 - 20070116767 - Chitosan-microparticles for ifn gene delivery The present invention provides particles comprising chitosan, or a derivative thereof, useful as delivery vehicles for polynucleotides encoding polypeptides, compositions comprising such particles and a pharmaceutically acceptable carrier, and methods for delivering polynucleotides using such particles. Optionally, the particles of the invention further comprise a lipid component. The present invention ... 05/17/07 - 20070110815 - Micronised azodicarbonamide, and the preparation and use thereof Azodicarbonamide (ADA) in the form of a micronised dry powder, said powder having a granulometric distribution of particles wherein the particles of the powder have a mean diameter (d50) equal to or less than 2 μm and a 90% diameter (d90) equal to or less than 4 μm. ... 05/10/07 - 20070104794 - Enzyme granules The present application relates to a steam treated pelletized feed composition comprising a granule comprising a core and a coating wherein the core comprises an active compound and the coating comprises a salt. ... 05/10/07 - 20070104793 - Process for making ceramic, mineral, and metal beads from powder A method is provided for synthesizing beads using starting ceramic, metal, or mineral powders. Typical size of these round beads can range from about 0.1 mm to about 10 mm based on the processing variables. In the method, a slip is obtained which contains a metal, ceramic, and/or mineral powder ... 05/10/07 - 20070104792 - Nanoparticulate tadalafil formulations The present invention is directed to compositions comprising nanoparticulate tadalafil, or a salt or derivative thereof, having improved bioavailability, faster rates of absorption and a faster onset of therapeutic effect. The nanoparticulate tadalafil particles of the composition are proposed to have an effective average particle size of less than about ... 05/03/07 - 20070098806 - Polymer-based antimicrobial agents, methods of making said agents, and products incorporating said agents The present invention relates to antimicrobial agents, methods for the production of these agents, and the use of these agents. The antimicrobial agent of the present invention includes a water-soluble polymer and oligodynamic metal ions which interact with counter-ions of the polymer such that the metal ions are bound to ... 05/03/07 - 20070098805 - Methods of making and using novel griseofulvin compositions The present invention is directed to nanoparticulate compositions comprising griseofulvin. The griseofulvin particles of the composition preferably have an effective average particle size of less than about 2 microns. ... 05/03/07 - 20070098804 - Solid particulate tadalafil having a bimodal particle size distribution Provided is a solid particulate tadalafil having a bimodal particle size distribution. ... 05/03/07 - 20070098803 - Small particle compositions and associated methods Small particle compositions are provided. The particles may have one or more desired features related to particle morphology, topology and crystallographic orientation. The small particle size coupled with such feature(s) can lead to significant property advantages in a variety of different applications including catalytic applications. ... 05/03/07 - 20070098802 - Organic nanoparticles and associated methods Methods of preparing organic nanoparticles are provided. Such methods can include generating a mixture of an organic material, a first liquid, and a second liquid, wherein the organic material is more soluble in the second liquid than in the first liquid. The methods can also include adding a third liquid ... 05/03/07 - 20070098801 - Particles shaped as platelets The present invention relates to polymer particles shaped as platelets and to a process of manufacturing such particles. The particles according to the invention exhibit a faster rate of dissolution in aqueous media than art-known particles. ... 05/03/07 - 20070098800 - Therapeutic compositions The present invention provides new formulations of injectable particles (e.g. microspheres) useful for intra-articular (i.a.) injection. The formulations are made of biocompatible polymers that biodegrade to generate NSAIDs, ad are useful for treating inflamed joints, thus providing safe, long-lasting relief of joint pain and swelling. In one embodiment, the present ... 04/26/07 - 20070092576 - Compositions containing opioid antagonists Compositions containing opioid antagonists are disclosed, particularly alvimopan and its active metabolite in solid dosage forms, where the drug is uniformly distributed, achieves the desired bioavailability, and is stable. Methods of preparing and using the compositions containing opioid antagonists are also disclosed. The results are achieved by a combination of ... 04/26/07 - 20070092575 - Compositions for administering rnaiii-inhibiting peptides Compositions comprising RIP are advantageously formulated in compositions allowing sustained release and protection from degradation, and improved therapeutic efficacy. To that end, RIP compositions may be delivered to the skin or mucosal membranes as a salve or the like. Alternatively or additionally, RIP compositions may be administered in polymeric nanoparticle ... 04/26/07 - 20070092574 - Controlled released compositions The compositions disclosed herein are for use as controlled release therapeutics for the treatment of a wide variety of diseases. In particular, the compositions provide water soluble bioactive agents, organic ions and polymers where the bioactive agent is efficiently released over time with minimal degradation products. The resulting controlled release ... 04/12/07 - 20070082055 - Stable micronized candesartan cilexetil and methods for preparing thereof The invention encompasses sable candesartan cilexetil of fine particle size, wherein desethyl-candesartan (desethyl-CNS) within the stable candesartan cilexetil does not increase to more than about 0.1% w/w by HPLC relative to the initial amount of candesartan cilexetil, when the stable candesartan cilexetil is maintained at a temperature of about 55° ... 04/12/07 - 20070082054 - Particle size reduction of bioactive compounds The invention provides a method for reducing the average size of biologically active compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having biologically active compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of ... 04/05/07 - 20070077307 - Pharmaceutical compositions The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester. ... 04/05/07 - 20070077306 - Apatite particle, method of producing the same, apatite particle-gene complex, and method of gene transfection When a solution of an inorganic phosphoric acid, added to with calcium ions and magnesium ions, is incubated for a preset time duration, an apatite particle obtained is reduced in size, depending on the concentration of the magnesium ions. By employing an apatite particle, for which the concentration of the ... 03/29/07 - 20070071827 - Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also ... 03/29/07 - 20070071826 - Method for preparing nano-scale or amorphous particle using solid fat as a solvent The present invention relates to a method for preparing nanoscale or amorphous particles using solid fat as a solvent. According to the present invention, nanoscale or amorphous particles of active ingredients are prepared by using fat as a solvent, wherein the fat is in solid phase at room temperature. The ... 03/29/07 - 20070071825 - Device and method for making particles Device for continuously producing particles, consisting of a homogenising compartment (1) including at least one inlet (2) for feeding in an organic phase, an inlet (3) for feeding in an aqueous phase, a mixing system (4) and an outlet (5). ... 03/22/07 - 20070065517 - Modafinil pharmaceutical compositions Pharmaceutical compositions comprising modafinil in the form of particles of defined size and methods for preparing same. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug. ... 03/22/07 - 20070065516 - Composition improved in the solubility or oral absorbability An object of the present invention is to provide a composition improved in the solubility or oral absorbability. The present invention provides a composition which comprises three components of a slightly water-soluble component, a surfactant and a hydrophilic polymer, and is obtainable by wet granulation in the presence of water. ... 03/22/07 - 20070065515 - Methods and compositions for treating skin lines and wrinkles and improving skin quality Methods and compositions for improving skin quality are disclosed. The methods include applying a solution of about 20-30% pre-wetting agent, such as hyaluronic acid, to a skin surface with concurrent dermabrasion treatment. These methods lead to significant improvement in the treatment of skin aging. Compositions for improving skin quality are ... 03/22/07 - 20070065514 - Method for enhancing immune responses in mammals The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to ... 03/15/07 - 20070059375 - Tissue treatment A method of treating tissue includes placing substantially spherical polymer particles in the tissue. The particles include an interior region having relatively large pores and a first region substantially surrounding the interior having fewer relatively large pores than the interior region. ... 03/15/07 - 20070059374 - Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle. ... 03/15/07 - 20070059373 - Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and ... 03/15/07 - 20070059372 - Use of autologous sediment from fluid aspirates as vehicles for drug delivery A method of using fluid aspirates as vehicles for drug delivery by collecting a fluid aspirate such as synovial joint effusion, pleural effusion, pericardial effusion, or ascites from a patient and centrifuging the fluid aspirate to provide a supernatant and a sedimented material. The sedimented material can optionally be further ... 03/15/07 - 20070059371 - Nanoparticulate ebastine formulations The invention is directed to compositions comprising at least one nanoparticulate H1-histamine receptor antagonist, such as ebastine or a salt or derivative thereof, having improved dissolution rate providing a faster onset of drug availability. The nanoparticulate H1-histamine receptor antagonist particles, such as ebastine, have an effective average particle size of ... 03/15/07 - 20070059370 - Method and apparatus for fabricating nanoparticles An apparatus and method for forming nanoparticles employs an inkjet dispenser and a nanoparticle formation device. The inkjet dispenser includes at least one orifice. A liquid solution with a substance to be transformed into nanoscale is received in the inkjet dispenser, and is dispensed from the at least one orifice ... 03/08/07 - 20070053989 - Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents This invention is directed to an apparatus and method for producing microparticles comprising pharmacologically active agents and biodegradable polymers. The apparatus includes a spinning disk containing a reservoir in the center thereof and a flat inclined surface. The apparatus optionally includes serrations and/or a flat surface beneath the periphery of ... 03/08/07 - 20070053988 - Monodispersed solid lipid particle compositions A composition includes a monodispersed lipid phase which is dispersed in a continuous aqueous phase, wherein the lipid phase includes at least one crystallizable lipid, at least one active ingredient and at least one compound including two chains of fatty acids and one glycol polyethylene chain. A method for the ... 03/01/07 - 20070048384 - Pharmaceutical compositions The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester. ... 03/01/07 - 20070048383 - Self-assembled endovascular structures The present invention is directed to the formation of structures in situ through the principles of ligand binding. These structures are efficacious, for example, for tissue repair as well as for short- and long-term disease and condition management. According to one aspect of the invention, an injectable composition comprising self-assembling ... 02/22/07 - 20070042050 - Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression Polynucleotides encoding at least one immunizing antigen whose expression is controlled by a promoter derived from a gene encoding a co-stimulatory molecule are provided. The polynucleotides may also encode adjuvants. Compositions comprising at least one immunizing agent and at least one cytokine that enhance dendritic cell stimulation and/or survival are ... 02/22/07 - 20070042049 - Nanoparticulate benidipine compositions The present invention relates to nanoparticulate benidipine compositions having improved bioavailability. The compositions comprise benidipine particles having an effective average particle size of less than about 2000 nm and may be useful in the prevention and treatment of hypertension, renal parenchymal hypertension and angina pectoris. ... 02/22/07 - 20070042048 - Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and ... 02/22/07 - 20070042047 - Vaccines The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumours. In particular, the construct comprises a fusion between a heat shock protein gene HSP70, typically from Mycobacterium tuberculosis and MUCl-1 or derivative thereof. The invention ... 02/15/07 - 20070036868 - Particulate vitamin composition A particulate composition comprising (a) an oil of a vitamin, an oil containing one or more vitamin or a derivative, (b) a gelling agent of vegetable origin, having a glass transition point greater than 20° C., and (c) a protein, except gelatine. ... 02/15/07 - 20070036867 - Controlled and sustained gene transfer mediated by thiol-modified polymers A delivery system employing nanoparticles of thiolated chitosan which complex with nucleic acids or other drugs. The system utilizes an approximately 33 kDa thiol-modified chitosan derivative resulting in highly effective gene delivery. Thiolation of chitosan resulted in reduced density of positive charges and DNA binding capacity. However, thiolated chitosan carrying ... 02/08/07 - 20070031502 - Pharmaceutical composition for the treatment of acute disorders A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active ... 02/01/07 - 20070026081 - Microparticles Microparticles comprising or consisting of a therapeutic agent having a particle density of at least 80% of the solid agent and a shape factor of 1 to 5. The microparticles may be produced by spray drying and may be used in needleless injection. ... 02/01/07 - 20070026080 - Manufacturing process for tigecycline Disclosed herein is a manufacturing process for the preparation of tigecycline suitable for intravenous infusion. ... 02/01/07 - 20070026079 - Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels Provided are methods of increasing KATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a ... 02/01/07 - 20070026078 - Pharmaceutical co-crystal compositions A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, ... 02/01/07 - 20070026077 - Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component The invention relates to a method of producing dosage units of a solid drug form containing as the active substance warfarin sodium salt in an amount of 1 to 10 mg and having high degree of content uniformity satisfying the Bergum criterion, wherein an aqueous solution of warfarin sodium salt ... 02/01/07 - 20070026076 - Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins T cell immune responses are enhanced by presentation of antigen to CD8+ T cells using a chimeric nucleic acid immunogen or vaccine that links DNA encoding an antigen with DNA encoding a polypeptide that targets or translocates the antigenic polypeptide to which it is fused (immunogenicity-potentiating polypeptides or “IPP”). By ... 01/25/07 - 20070020337 - Paclitaxel-based antitumor formulation Antitumor formulation based on nanoparticles of paclitaxel and human serum albumin as obtained by the addition of a biocompatible acid to an aqueous albumin solution before this is mixed with paclitaxel during the nanoparticle production process, the injectable solutions of this formulation having a pH between 5.4 and 5.8 and ... 01/18/07 - 20070014865 - Chemically stable, dry-flow, low compact, dust free, soluble granules of phosphoroamidothioate prepared by a process of dry granulation by agitative balling Chemically stable, dry-flow, low compact, dust free, soluble granules of phosphoroamidothioate are prepared using a substantially dry granulation process including an agitative balling process. In a preferred embodiment, spherically shaped acephate granules are produces without the intentional addition of water and/or solvents. ... 01/18/07 - 20070014864 - Novel pharmaceutical granulate One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable ... 01/18/07 - 20070014863 - Method of controlling paticle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method Nanoparticles containing retinoic acid have reduced irritancy of retinoic acid and are suitable for subcutaneous or intravenous administration, as well as for use in sustained-release preparation. The high skin permeability of the nanoparticles makes them suitable for use in pharmaceutical or non-pharmaceutical external preparations or cosmetics intended for skin application. ... 01/11/07 - 20070009604 - Process A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid ... 01/11/07 - 20070009603 - Compositions comprising fenofibrate and atorvastatin The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about ... 01/04/07 - 20070003630 - Anti-angiogenic compositions and methods of use The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions. ... 01/04/07 - 20070003629 - Anti-angiogenic compositions and methods of use The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions. ... 01/04/07 - 20070003628 - Nanoparticulate clopidogrel formulations The present invention is directed to compositions comprising a nanoparticulate clopidogrel, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate clopidogrel particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of pathologies induced ... 12/28/06 - 20060292225 - Water soluble analgesic formulations and methods for production A water soluble analgesic composition includes a plurality of granules. Each of the granules includes a substrate core and a coating disposed on the substrate core forming an agglomerated product, the coating including a salt of an analgesic, but substantially no particles of a non-salt form of the analgesic. The ... 12/28/06 - 20060292224 - Pharmaceutical composition This invention relates to pharmaceutical formulations comprising particles with a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule. The invention also relates to methods of forming particles comprising a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive ... 12/21/06 - 20060286175 - Stabilized particle dispersions containing nanoparticles In one aspect, the invention provides a stable dispersion comprising a continuous phase comprising a continuous liquid phase and a plurality of organic nanoparticles; and a dispersed phase comprising particles dispersed in the continuous phase. ... 12/21/06 - 20060286174 - Granular sustained release preparation and production thereof There is disclosed a novel sustained release granular resin-pharmaceutical composition comprising an ion exchange resin complexed with a pharmaceutical material wherein said complex is embedded into and on the surface of a diffusion barrier material. There is also disclosed a novel process for preparing the granulated complex wherein an aqueous ... 12/21/06 - 20060286173 - Drug delivery system for sub-tenon s capsule adminstration of fine grains The present invention provides a drug delivery system that is a sustained drug delivery system targeting a tissue in the posterior segment of the eye accompanied by low degree of tissue invasiveness without need of frequent administration, and enables selective delivery of a drug to the posterior segment of the ... 12/14/06 - 20060280801 - Compositions and method for the reduction of post-operative pain An organic liquid capable of solubilizing, dispensing or suspending the analgesic, such as esters of monohydric alcohols with aliphatic monocarboxylic acids; C2-C18 monohydric alcohols with polycarboxylic acids; C8-C30 monohydric alcohols; tocopherol and esters thereof with mono or polycarboxylic acids; free carboxylic acids such as oleic, capric, and lauric; dialkyl ethers ... 12/14/06 - 20060280800 - Tanaproget compositions containing ethinyl estradiol Compositions containing micronized tanaproget, or a pharmaceutically acceptable salt thereof, and ethinyl estradiol and methods of preparing the same are provided. Also provided are kits containing the compositions, methods of contraception and hormone replacement therapy including administering a composition containing micronized tanaproget and ethinyl estradiol. ... 12/14/06 - 20060280799 - Carrier particles A carrier particle (10) is arranged in use to encapsulate and carry a payload molecule (4) to a target biological environment, and comprises an internal cavity (8) in which a payload molecule (4) is contained. The cavity (8) is surrounded by a perm-selective hydrogel layer (6), and the payload molecule ... 12/07/06 - 20060275375 - Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly The invention relates to capsules coated with a polyelectrolyte shell and methods for the production thereof. ... 12/07/06 - 20060275374 - Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly The invention relates to capsules coated with a polyelectrolyte shell and methods for the production thereof. ... 12/07/06 - 20060275373 - Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly The invention relates to capsules coated with a polyelectrolyte shell and methods for the production thereof. ... 12/07/06 - 20060275372 - Nanoparticulate imatinib mesylate formulations The present invention is directed to a nanoparticulate compositions of imatinib mesylate, or a salt or derivative thereof, having improved pharmacokinetic profiles and reduced fed/fasted variability. The nanoparticulate imatinib mesylate particles of the composition have an effective average particle size of less than about 2000 nm and are useful in ... 12/07/06 - 20060275371 - Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells Methods and materials for delivering biologically active molecules to cells in vitro or in vivo are provided. The methods and materials use carbon nanotubes or other hydrophobic particles, tubes and wires, functionalized with a linking group that is covalently bound to the nanotubes, or, alternatively, to the biologically active molecule, ... 11/30/06 - 20060269612 - Intracellular thermal ablation using nano-particle electron spin resonance heating This invention pertains to the use of spin resonance absorption heating as a therapeutic treatment method wherein electron spin resonance absorption of superparamagnetic (SPM) nanoparticles can be used as an intracellular heating method, more preferably as an in vivo heating method that can be utilized in a variety of therapeutic ... 11/30/06 - 20060269611 - Prevention and treatment of androgen-deprivation induced osteoporosis This invention provides a method of treating androgen-deprivation induced osteoporosis, bone fractures or loss of bone mineral density (BMD) in a male human subject suffering from prostate cancer by administering a pharmaceutical composition comprising Toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any ... 11/30/06 - 20060269610 - Method for producing water dispersible dry powders from poorly soluble compounds The invention relates to a method for producing water dispersible dry powders from hardly soluble compounds, whereby a dispersion is provided, containing the poorly soluble compound in a microdispersed form in a dispersion agent. The dispersion of the poorly soluble compound is concentrated by tangential-filtration and the dispersion agent is ... 11/23/06 - 20060263436 - Antifungal compositions with improved bioavailability The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by ... 11/23/06 - 20060263435 - Inhibitors of ribonucleotide reductase subunit 2 and uses thereof The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs. ... 11/23/06 - 20060263434 - Combinations and modes of administration of therapeutic agents and combination therapy The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations ... 11/23/06 - 20060263433 - Suspension formulation of interferon A suspension formulation of interferon includes a non-aqueous, single-phase vehicle including at least one polymer and at least one solvent, the vehicle exhibiting viscous fluid characteristics, and an interferon contained in a particle formulation dispersed in the vehicle. The particle formulation includes a stabilizing component comprising one or more stabilizers ... 11/23/06 - 20060263432 - Polyhydroxyalkanoate-containing magnetic structure, and manufacturing method and use thereof A structure containing polyhydroxyalkanoate and a magnetic substance includes an external phase part containing polyhydroxyalkanoate and an internal phase part contained in the external phase part, at least one of the external phase part and the internal phase part containing a magnetic substance. Accordingly, provided is a microcapsule, which can ... 11/16/06 - 20060257494 - Coated tablets Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, ... 11/16/06 - 20060257493 - Nanoparticulate delivery systems for treating multi-drug resistance An encapsulated delivery system, and, in particular, a nanoparticulate delivery system representing a qualitatively different approach to overcoming multi-drug resistance while simultaneously administering the chosen drug treatment to a patient, e.g., in a site-specific manner, is disclosed. A composition according to the invention includes a therapeutically effective amount of one ... 11/16/06 - 20060257492 - Suspension of calcium phosphate particulates for local delivery of therapeutic agents Disclosed herein are methods for preparing and using porous, crystalline biomimetic bioactive compositions of calcium phosphate with at least one therapeutic agent. The bioactive composition has strong adsorption properties for therapeutic agents which adsorb to the calcium phosphate with a high affinity. The bioactive composition also provides a sustained release ... 11/16/06 - 20060257491 - Dry powder composition comprising co-jet milled particles for pulmonary inhalation The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process. ... 11/16/06 - 20060257490 - Formulation based on phospholipids The invention relates to a formulation containing a phospholipid constituent as a physiologically active ingredient, the formulation itself being in a water-dispersible granulated form and containing a fructane constituent, in addition to the phospholipid constituent, as a formulation auxiliary agent, in a weight ratio of 5 to 70: 95 to ... 11/16/06 - 20060257489 - Fine particles, method and device for preparation thereof, and agent for parenteral injection and method for production thereof In a method for finely pulverizing an organic compound 5 in treatment target liquid 2 to manufacture fine particles of the organic compound 5, a laser beam having a wavelength which is longer than the light absorption band of the organic compound 5 or corresponds to an absorption wavelength of ... 11/09/06 - 20060251728 - Crystalline forms of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-[4-((r)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments The invention relates to crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments. ... 11/09/06 - 20060251727 - Supplemental dietary composition for increasing muscle size, strength, athletic performance and/or exercise capacity The present invention provides for a diet supplement comprising creatine ethyl ester HCl or derivatives thereof, creatine alpha-ketoglutarate, and alpha lipoic acid, wherein the supplemental dietary composition increases muscle size, strength, athletic performance and/or exercise capacity. Methods of using and producing the composition are also disclosed. The supplemental dietary composition ... 11/09/06 - 20060251726 - Bioactive fus1 peptides and nanoparticle-polypeptide complexes A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the ... 11/09/06 - 20060251725 - Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof Provided are nanoparticles prepared by the aggregation of cucurbituril derivatives and having a particle size of 1 to 1,000 nm, a pharmaceutical composition in which a pharmaceutically active substance is loaded into the nanoparticles, and preparation methods thereof. ... 11/02/06 - 20060246143 - Targeted therapy via targeted delivery of energy susceptible nanoscale magnetic particles The present invention relates generally to targeted therapy with RNA interference, more specifically, to energy susceptible nanoscale material compositions, devices for use with magnetic material compositions, and methods related thereto for targeted therapy via targeted delivery of energy susceptible nanoscale magnetic particles carrying short interfering RNA constructs. ... 11/02/06 - 20060246142 - Nanoparticulate quinazoline derivative formulations The present invention is directed to nanoparticulate quinazoline derivative compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The nanoparticulate quinazoline derivative particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hyperproliferative disorders, such as cancer ... 11/02/06 - 20060246141 - Nanoparticulate lipase inhibitor formulations The invention relates to nanoparticulate lipase inhibitor compositions having improved pharmacokinetic profiles. The nanoparticulate lipase inhibitor compositions have an effective average particle size of less than about 2000 nm and are useful in the treatment of obesity and related diseases. ... 10/26/06 - 20060240113 - Anti-angiogenic compositions and methods of use The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions. ... 10/26/06 - 20060240112 - Process for the purification of riboflavin The invention relates to a process for the purification of riboflavin comprising the steps of (a) precipitating a first crystalline form of riboflavin, (b) isolating the first crystalline form of riboflavin, (c) transforming the first crystalline form of riboflavin into a second crystalline form of riboflavin under conditions that decompose ... 10/12/06 - 20060228421 - Device for moving magnetic nanoparticles through tissue The movement of magnetically responsive nanoparticles through a membrane is significantly enhanced by using a varying magnetic field gradient. The magnetic field varies in intensity and/or direction and can be achieved by mechanically varying the position of a magnet with respect to the membrane, or by oscillating the strength of ... 10/12/06 - 20060228420 - Pharmaceutical compositions comprising microparticles for delivery into neurons A method is provided for the delivery into a neuron of a microparticle of average particle diameter 0.5 μm containing a pharmaceutically active substance, comprising the administration of said particle to said neuron. Also provided are methods for the treatment of diseases of the nervous system comprising the use of ... 10/12/06 - 20060228419 - Solvent-free process for preparation of hydrophilic dispersions of nanoparticles of inclusion complexes The invention provides a solvent-free process for the preparation of a hydrophilic dispersion comprising nanoparticles of an hydrophilic inclusion complex consisting essentially of nanosized particles of an active compound and an amphiphilic polymer which wraps said active compound such that non-valent bonds are formed between said compound and said polymer ... 10/05/06 - 20060222716 - Colloidal solid lipid vehicle for pharmaceutical use The invention provides a drug carrier that includes a solid lipid nanoparticle (SLN), wherein the SLN includes tocopherol or a derivative thereof. The invention also provides a pharmaceutical composition that includes a SLN and a biologically active compound, wherein the SLN comprises tocopherol or a derivative thereof. The present invention ... 10/05/06 - 20060222715 - Particles containing an acitve agent in the form of a co-precipitate The invention relates to particles containing an active agent in the form of a co-precipitate, to a method for producing said particles and to pharmaceutical forms containing said particles. ... 10/05/06 - 20060222714 - Agent for preventing and ameliorating constipation A novel agent for preventing and healing constipation which heals the symptom of constipation very effectively and entails absolutely no side effect is provided. This agent for preventing and healing constipation is formed by containing a hydrogen of a polyvalent metal salt of alginic acid possessing a spherical or ovaloid ... 09/28/06 - 20060216353 - Nanoparticulate corticosteroid and antihistamine formulations Compositions comprising a nanoparticulate corticosteroid and an antihistamine are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining an antihistamine with a nanoparticulate ... 09/28/06 - 20060216352 - Rapid-acting pharmaceutical composition A pharmaceutical composition for the treatment of acute disorders is described. The composition includes an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active ... 09/21/06 - 20060210640 - Process for producing nanoparticles by spray drying Nanoparticles of a compound are produced by spraying a solution of the compound into a heated chamber. The resulting product comprises a free flowing mixture of nanoparticles of the compound. ... 09/21/06 - 20060210639 - Nanoparticulate bisphosphonate compositions Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal. ... 09/21/06 - 20060210638 - Injectable compositions of nanoparticulate immunosuppressive compounds The invention is directed to an injectable nanoparticulate immunosuppressant composition for the formation of a subcutaneous or intramuscular depot. The invention is also directed to an injectable composition of nanoparticulate tacrolimus and/or sirolimus which eliminates the need to use polyoxyl 60 hydrogenated castor oil (HCO-60) and/or polysorbate 80 as a ... 09/21/06 - 20060210637 - Stable tablet dosage forms of proton pump inhibitors This invention relates to a method of making oral formulations of practically water insoluble, or very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of use thereof. The oral dosage form has a core tablet of compressed particles composed of powder particles of a ... 09/21/06 - 20060210636 - Nanoscale core/shell particles and the production thereof In methods for the production of nanoscale particles having a so-called core and at least one so-called shell, either nanoscale particles of an inorganic material having a particle size of <100 nm or nanoscale particles of a magnetic material having a particle size of <100 nm are used as the ... 09/14/06 - 20060204586 - Time release calcium sulfate matrix for bone augmentation A bone-growth stimulating composition for forming a resorbable implant, methods for making such a composition and a corresponding putty/paste material. In some embodiments of the invention, such a material includes a plurality of particles having a predetermined size and comprising a first calcium sulfate compound and a resorbable polymer in ... 09/14/06 - 20060204585 - Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both ... 09/14/06 - 20060204584 - Materials and methods relating to polyions and substance delivery Materials and method are disclose for delivering a desired substance to a target site, using a layered carrier in which the carrier and the substance together form at least three layers which associate by ionic interaction at the first pH, where at least one layer comprises a charge switch material ... 09/07/06 - 20060198896 - Aerosol and injectable formulations of nanoparticulate benzodiazepine Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam, ... 09/07/06 - 20060198895 - Azithromycin powder for oral suspension compositions Non-caking azithromycin powder for oral suspension compositions and methods of making such compositions are disclosed. The compositions comprise a hydrated buffer, preferably a hydrate of sodium phosphate such as tribasic sodium phosphate dodecahydrate. ... 09/07/06 - 20060198894 - Stabilized, solid-state polypeptide particles The present invention includes solid-state polypeptide particles containing a polypeptide material that is stabilized against degradation at temperatures that approximate or exceed physiological conditions. In each embodiment, the polypeptide particles of the present invention incorporate a polypeptide material that is stabilized against degradation by one or more stabilizing conditions. Because ... 09/07/06 - 20060198893 - Aqueous dispersion comprising stable nanoparticles of a water-insoluble pyrrole carboxamide and excipient like middle chain triglycerides Also claimed are stable dispersions prepared by the process, solid particles prepared by the process and use of such particles. ... 08/31/06 - 20060193921 - Hydrophilic beads for use in topical formulations A composition and method for producing hydrophilic beads for use in topical formulations is described as generally including gellan gum, salts of divalent cations and water. Disclosed features and specifications may be variously controlled, adapted or otherwise optionally modified to realize improved production and/or use of hydrophilic beads to achieve ... 08/31/06 - 20060193920 - Nanoparticulate compositions of mitogen-activated protein (map) kinase inhibitors Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. ... 08/31/06 - 20060193919 - Complex of drug-carbon nanohorn and a process for producing the complex The present invention provides a carbon nanohorn complex that is excellent in characteristics of adsorption or inclusion of drugs and release, in particular, a sustained release of drugs as a novel drug carrier in drug delivery systems, as well as a process for producing the complex. The complex of drug ... 08/24/06 - 20060188581 - Rasagiline formulations of improved content uniformity Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses. ... 08/24/06 - 20060188580 - Anti-microbial granules Antimicrobial granules comprising granular materials coated with antimicrobial metal agents for use in various surface coating and grouting materials are provided. The antimicrobial granules have utility in imparting durable, safe, inexpensive and powerful antimicrobial properties to materials into which they are incorporated, such as epoxy coating and grouts for surgical ... 08/24/06 - 20060188579 - Novel process The invention relates to a novel procedure for the production of a high yield of small crystalline particles of a narrow size distribution. ... 08/24/06 - 20060188578 - Hyaluronic acid nanoparticles The invention relates to hyaluronic acid nanoparticles for the administration of at least one active ingredient. The inventive nanoparticles comprise hyaluronic acid in salt form a positively-charged polymer, a polyanionic salt and at least one active ingredient. The method of obtaining the aforementioned nanoparticles comprises the following steps consisting in: ... 08/24/06 - 20060188577 - Element having bioactive substance fixed thereto By using a biologically active substance-immobilized device, which comprises a base particle comprising a core particle and an organic compound having two or more hydrophilic groups and immobilized on the core particle by a chemical bond and a biologically active substance bonded to the base particle via the organic compound, ... 08/17/06 - 20060182809 - System for transporting active substances in a biological system A stabilizer-free system for transporting active substances in a biological system of one or more active substances and magnetic particles is characterized in that the particles are provided with active substance(s) on at least part of their surface. Modification of the magnetic particles is not absolutely required in this system. ... 08/17/06 - 20060182808 - Antisolvent solidification process The present invention relates to a antisolvent solidification process wherein a liquid medium comprising at least one organic or inorganic compound which is to be solidified is forced through a membrane into one or more antisolvents, or wherein one or more antisolvents are forced through a membrane into a liquid ... 08/17/06 - 20060182807 - Copolymer and hemoprotein based novel compounds and uses thereof The invention relates to novel compounds, characterized in that they comprise a hemoprotein which is associated with a sequenced block copolymer, comprising an hydrophilic segment which is an oligo or polysaccharide linked to at least one hydrophobic segment of formula (1) wherein x represents H or an radical which is ... 08/10/06 - 20060177513 - Embolization using poly-4-hydroxybutyrate particles Absorbable particles which comprises poly-4-hydroxybutyrate and/or its copolymers are formulated in injectable suspension suitable for prophylactic or therapeutic embolization, which comprises administering to a human or animal the injectable suspension process for producing particles of the poly-4-hydroxybutyrate and/or its copolymer. ... 08/10/06 - 20060177512 - Process for preparing formulations of lipid-regulating drugs A process for preparing a formulation of a lipid-regulating drug comprising dissolving said lipid-regulating drug in a solvent free of surfactant, premixing an excipient, wet granulating the drug solution/excipient mixture, drying the mixture and forming a final dosage form. ... 08/03/06 - 20060172011 - Medical treatment Provided is a particle capable of being inserted into or taken up by a cell comprising i) a polynucleotide coding for a modulator of Notch signalling; and ii) a polynucleotide coding for an antigen or antigenic determinant thereof. Methods for using the particles are also described. ... 08/03/06 - 20060172010 - Process for preparing particles containing an antiviral A process for preparing a particle comprising a co-precipitate surrounding a neutral hydrophilic carrier, said process comprising spraying an organic solution on a neutral hydrophilic carrier, said solution comprising at least one triazine or pyrimidine active ingredient having HIV inhibiting properties, one surface active agent, and one hydrophilic polymer, wherein ... 08/03/06 - 20060172009 - The formulation and presentation of medicaments A medicament package (10,30) comprises a vessel (12,32) adapted to hold a quantity of a liquid vehicle. The vessel (12,32) has an opening formed therein, to which opening is bonded a deformable enclosure (18,38). A medicament container (20) that contains a unit dose of a medicament is received within the ... 07/27/06 - 20060165806 - Nanoparticulate candesartan formulations The present invention is directed to compositions comprising a candesartan, such as candesartan cilexitil. The candesartan particles of the composition have an effective average particle size of less than about 2000 nm. The candesartan compositions of the invention are useful in the treatment of hypertension or related cardiovascular conditions. ... 07/27/06 - 20060165805 - Magnetic pole matrices useful for tissue engineering and treatment of disease A magnetic pole matrix chip facilitating the grinding of magnetic particles carrying matter effective for treating a disease or promoting tissue engineering to a disease site or a tissue engineering site, respectively ... 07/27/06 - 20060165804 - Polymer compositions for administration to animals Particulate embolotherapeutic compositions are described in which the particles comprise a matrix polymer expressing at surfaces available for interaction with biological molecules or, usually, blood cells, express zwitterionic groups, usually phosphoryl choline groups. The particles have suitable size and compressibility, for instance controlled by controlling the water content, for use ... 07/20/06 - 20060159768 - Quetiapine granules Granule formulation of quetiapine and pharmaceutically acceptable salt thereof are described, as are their preparation and their use in treating diseases of the central nervous system such as psychotic disease conditions including schizophrenia. ... 07/20/06 - 20060159767 - Nanoparticulate bicalutamide formulations The present invention is directed to compositions comprising an acylanilide, such as bicalutamide, having improved solubility in water. The bicalutamide particles of the composition have an effective average particle size of less than about 2000 nm, and are useful in the treatment of prostate cancer. ... 07/20/06 - 20060159766 - Nanoparticulate tacrolimus formulations The present invention is directed to nanoparticulate tacrolimus compositions. The composition comprising tacrolimus particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer. ... 07/13/06 - 20060153923 - Nanoparticles of polypoxyethylenated derivatives The invention relates to nanoparticles of polyoxyethylenated derivatives, having a size of less than 1 micrometer, for the administration of pharmaceutically- or cosmetically-active ingredients. The inventive nanoparticles comprise a biodegradable polymer, a polyoxyethylene-derived block copolymer and at least one pharmaceutically- or cosmetically-active ingredient. The invention further relates to the method ... 07/13/06 - 20060153922 - Light induced immobilisation The present invention involves a method of coupling disulfide bridge containing proteins to a carrier by inducing the formation of thiol groups on a protein with irradiation, and coupling the protein to the carrier. The formation of thiol group(s) in the protein is a consequence of the disruption of disulfide ... 07/13/06 - 20060153921 - Method for preparation of particles from solution-in-supercritical fluid or compressed gas emulsions The present invention provides a method of producing particles from solution-in-supercritical fluid or compressed gas emulsions. In accordance with the method of the invention, a solution that includes a solute dissolved in a solvent is contacted with supercritical fluid or compressed gas to form a solution-in-super critical fluid or compressed ... 07/06/06 - 20060147541 - Pharmaceutical preparation for rectal administration A pharmaceutical preparation for rectal administration by which a drug is retained in the affected region or the lower region of the rectum, where the drug is sustained-released is disclosed. The present invention is a pharmaceutical preparation for rectal administration comprising a coated drug-supported particle dispersed in a base, wherein ... 07/06/06 - 20060147540 - Non-hygroscopic and powdery amorphous pimecrolimus An amorphous pimecrolimus and processes for providing an amorphous pimecrolimus are provided. ... 07/06/06 - 20060147539 - Nanoparticles for protein drug delivery The invention discloses the nanoparticles composed of chitosan, poly-γ-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery. ... 07/06/06 - 20060147538 - Nanocomposite drug delivery composition The invention relates to a drug delivery composition comprising an active ingredient and a biologically inert material wherein the biologically inert material is a nanocomposite material. Preferably the biologically inert material is a polymer-clay nanocomposite comprising up to about 40% by weight of nano-sized (1-1000 nm) clay particles dispersed in ... 07/06/06 - 20060147537 - Stabilized pharmaceutical product The invention relates to the use of an adsorbent and a sealed package, for example an overwrap, to protect a pharmaceutical product in a solid state in the presence of a reducing sugar. ... 07/06/06 - 20060147536 - Method for removing fluids containing dissolved or suspended carbohydrates, lipids, metals, salts, and/or toxins from biological systems A means for reducing the levels of carbohydrates, lipids, metals, salts and/or toxins in biological systems thereby preventing or reducing weight gain, while reducing, for example, the incidence of atherosclerosis, hypertension, and toxic reactions, is provided. More specifically, the subject invention provides non-toxic, substantially non-degradable, optionally collapsible and/or expandable particles ... 07/06/06 - 20060147535 - Methods for and compositions of anticancer medicaments The present invention provides methods for and compositions of anticancer medicaments. These compositions are comprised of nanoparticles or microparticles produced by antisolvent technology. The particles can be used to treat cancerous tissues in humans or animals. ... 06/29/06 - 20060141052 - Drug microparticles Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them. ... 06/29/06 - 20060141051 - Drug microparticles Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them. ... 06/29/06 - 20060141050 - Drug microparticles Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them. ... 06/29/06 - 20060141049 - Triamcinolone compositions for intravitreal administration to treat ocular conditions Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps ... 06/29/06 - 20060141048 - (polyalkoxy)sulfonate surface modifiers The present invention is directed to novel compounds, methods of manufacture and methods of use. The present invention is also directed to solid drug/active agent particles having one or more of the compounds of the present invention associated with the surface thereof. The compounds of the present invention are comprised ... 06/29/06 - 20060141047 - Methods and compositions for delivery of catecholic butanes for treatment of obesity The present invention provides kits, methods and compositions for the treatment of obesity. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered ... 06/29/06 - 20060141046 - Particles for the delivery of active agents Formulations of active agent particles of less than 100 microns in a droplet of dispersant, which is coated with a matrix of cationic and anionic polymers, are efficient vehicles for delivering active agents to tissues such as ski |